SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 TO SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 ALEXION PHARMACEUTICALS, INC. - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, $.0001 PAR VALUE - -------------------------------------------------------------------------------- (Title of Class of Securities) 015351109 ------------ (CUSIP Number) Mark H. Swartz Executive Vice President c/o Tyco International (US) Inc. One Tyco Park Exeter, NH 03833 (603) 778-9700 Michael W. Lyons Corporate Counsel United States Surgical Corporation 150 Glover Avenue Norwalk, Connecticut 06856 (203) 845-1000 with a copy to: Frederick W. Kanner, Esq. Dewey Ballantine LLP 1301 Avenue of the Americas New York, New York 10019-6092 (212) 259-8000 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) DECEMBER 30, 1998 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box / /. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 7 Pages)
SCHEDULE 13D - ------------------------------------- -------------------------------------------- CUSIP NO. 015351109 PAGE 2 OF 7 PAGES --------------------------- ------- ------- - ------------------------------------- -------------------------------------------- - --------------------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Tyco International Ltd. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Not Applicable - --------------------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - --------------------------------------------------------------------------------------------- 3 SEC USE ONLY - --------------------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* Not Applicable - --------------------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - --------------------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Bermuda - --------------------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES BENEFICIALLY Not Applicable OWNED BY EACH REPORTING PERSON WITH ------------------------------------------------------------------------ 8 SHARED VOTING POWER Not Applicable ------------------------------------------------------------------------ 9 SOLE DISPOSITIVE POWER Not Applicable ------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER Not Applicable - --------------------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 - --------------------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / Not Applicable - --------------------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - --------------------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - --------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
SCHEDULE 13D - ------------------------------------ ---------------------------------- CUSIP NO. 015351109 PAGE 3 OF 7 ----------------------- ------- ------- PAGES - ------------------------------------ ---------------------------------- - ------------------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: United States Surgical Corporation S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 132518270 - ------------------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - ------------------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - ------------------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - ------------------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES Not Applicable BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH -------------------------------------------------------------------------- 8 SHARED VOTING POWER Not Applicable -------------------------------------------------------------------------- 9 SOLE DISPOSITIVE POWER Not Applicable -------------------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER Not Applicable - ------------------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 - ------------------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / Not Applicable - ------------------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
Tyco International Ltd., a Bermuda company ("Tyco") and United States Surgical Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Tyco ("US Surgical") hereby further amend and supplement Statement on 13D previously filed by Tyco and US Surgical (the "Schedule 13D") relating to the common stock $.0001 par value (the "Common Stock"), of Alexion Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), originally filed with the Securities and Exchange Commission (the "Commission") on February 29, 1996, as amended. The item numbers and responses thereto below are in accordance with the requirements of Schedule 13D. Unless otherwise indicated herein, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D. The term Reporting Persons means Tyco and US Surgical. The Schedule 13D is hereby amended as follows: ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) Number of Shares Beneficially Owned: As of the date hereof, the Reporting Persons own an aggregate of 0 shares of Common Stock of the Issuer. (b) Sole Power to Vote, Direct the Vote of, Dispose of, or Direct the Disposition of Shares: Not Applicable. (c) Recent Transactions: On December 30, 1998, the Reporting Persons sold 824,087 shares of Common Stock of the Issuer in open market transactions at a price of $11.625 per share. (d) Rights with Respect to Dividends on Sales Proceeds: Not Applicable. (e) Date of Cessation of Five Percent Beneficial Ownership: 12/30/98. (Page 4 of 7 Pages)
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Item 7 of the Schedule 13D is hereby amended and supplemented by the following: EXHIBIT NO. DESCRIPTION - ----------- ----------- 1 Agreement of Joint Filing pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended. (Page 5 of 7 Pages)
After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: January 21, 1999 TYCO INTERNATIONAL LTD. By: /s/ MARK H. SWARTZ ----------------------------------------- Name: Mark H. Swartz Title:Executive Vice President, Chief Financial Officer UNITED STATES SURGICAL CORPORATION By: /s/ MARK H. SWARTZ ----------------------------------------- Name: Mark H. Swartz Title: Vice President (Page 6 of 7 Pages)
Exhibit 1 Agreement of Joint Filing Pursuant to 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned persons hereby agree to file with the Securities and Exchange Commission the Statement on Schedule 13D (the "Statement") to which this Agreement is attached as an exhibit, and agree that such Statement, as so filed, is filed on behalf of each of them. IN WITNESS WHEREOF, the undersigned have executed this Agreement. TYCO INTERNATIONAL LTD. By: /s/ MARK H. SWARTZ ----------------------------------------- Name: Mark H. Swartz Title: Executive Vice President, Chief Financial Officer UNITED STATES SURGICAL CORPORATION By: /s/ MARK H. SWARTZ ----------------------------------------- Name: Mark H. Swartz Title: Vice President (Page 7 of 7 Pages)